PT  - JOURNAL ARTICLE
AU  - Else A. Aalbersberg
AU  - Daphne M.V. Huizing
AU  - Iris Walraven
AU  - Berlinda J. de Wit-van der Veen
AU  - Harshad R. Kulkarni
AU  - Aviral Singh
AU  - Marcel P.M. Stokkel
AU  - Richard P. Baum
TI  - Parameters to Predict Progression-Free and Overall Survival After Peptide Receptor Radionuclide Therapy: A Multivariate Analysis in 782 Patients
AID  - 10.2967/jnumed.118.224386
DP  - 2019 Sep 01
TA  - Journal of Nuclear Medicine
PG  - 1259--1265
VI  - 60
IP  - 9
4099  - http://jnm.snmjournals.org/content/60/9/1259.short
4100  - http://jnm.snmjournals.org/content/60/9/1259.full
SO  - J Nucl Med2019 Sep 01; 60
AB  - Peptide receptor radionuclide therapy (PRRT) is an effective treatment for patients with neuroendocrine neoplasms. The aim of this study was to identify clinical and treatment parameters associated with progression-free survival (PFS) and overall survival (OS). Methods: All patients treated from October 2002 until March 2016 at the Zentralklinik Bad Berka with at least 3 administrations of PRRT (maximal interval of 6 mo between consecutive administrations) were included. Data were collected in 5 categories: general patient characteristics, tumor characteristics, prior treatments, radioisotope used for PRRT, and blood chemistry. Survival was analyzed using Kaplan–Meier curves. Univariate and multivariate Cox regression analyses were performed to identify parameters associated with PFS and OS. Results: In total, 782 patients were included, with a median follow-up of 36 mo. The median PFS and OS were 22 and 53 mo, respectively. Parameters associated with lower PFS in the multivariate analysis were a Ki-67 of more than 5%, previous treatment with interferon-α and chemotherapy, presence of diabetes, and chromogranin-A (CgA) levels higher than 336 μg/L. Parameters associated with lower OS were a Ki-67 of more than 10%, performance status of at least 1, previous chemotherapy and ablation, and CgA levels higher than 112 μg/L. Conclusion: Higher Ki-67 values, as well as higher CgA levels and previous chemotherapy, had a negative outcome on both PFS and OS. Furthermore, PFS was negatively associated with previous interferon-α treatment and diabetes, whereas lower OS was related to prior ablation and higher performance status.